Sign in Sign up for free

Last updated: 7 June 2024 at 5:09pm EST

Thomas Bumol Net Worth



Thomas Bumol biography

Dr. Thomas F. Bumol Ph.D. serves as Independent Director of the Company. Dr. Bumol has served on our board of directors since February 2019 and as chairman of our scientific committee since September 2019. Dr. Bumol is executive director of the Allen Institute for Immunology in Seattle, Washington, a position he assumed in March 2018. Dr. Bumol joined the Allen Institute following a 35-year career at Eli Lilly and Company. Dr. Bumol held various positions at Eli Lilly from 1982 until his retirement in December 2017. He was most recently the senior vice president of biotechnology and immunology research and the site head of Eli Lilly’s Biotechnology Center in San Diego, California. While at Eli Lilly, Dr. Bumol’s teams and collaborators advanced over 100 molecules into clinical development, including TRULICITY® (dulaglutide), TALTZ®(ixekizumab), EMGALITY® (galcanezumab) and mirikizumab. Through strategic alliances, he and his teams also helped develop and support REOPRO® (abciximab) with Centocor Inc. (n/k/a Janssen Pharmaceutical Cos.) as well as OLUMIANT® (baricitinib) with Incyte Corporation. Dr. Bumol has over 50 publications and reviews and eight issued U.S. patents. He serves on the University of Michigan Technology Transfer National Advisory Board, on the Board of Directors of PanTheryx, and as an advisor to Lilly Ventures. Dr. Bumol earned his B.S. degree in microbiology from the University of Michigan and his Ph.D. in microbiology-immunology from the University of Minnesota. He completed postdoctoral studies through a fellowship in the Department of Molecular Immunology at Scripps Research in La Jolla, California. Our nominating and governance committee has concluded that Dr. Bumol should continue to serve on the board of directors based on his scientific expertise in drug discovery and development and experience in strategic partnering and other collaborations within the life sciences and pharmaceutical industries.

What is the salary of Thomas Bumol?

As the Independent Director of Omeros, the total compensation of Thomas Bumol at Omeros is $177,808. There are 7 executives at Omeros getting paid more, with Gregory Demopulos having the highest compensation of $4,825,130.



How old is Thomas Bumol?

Thomas Bumol is 66, he's been the Independent Director of Omeros since 2019. There are 4 older and 25 younger executives at Omeros. The oldest executive at Omeros Corporation is Ray Aspiri, 83, who is the Independent Director.

What's Thomas Bumol's mailing address?

Thomas's mailing address filed with the SEC is 201 ELLIOTT AVENUE WEST, , SEATTLE, WA, 98119.

Insiders trading at Omeros

Over the last 15 years, insiders at Omeros have traded over $719,810 worth of Omeros stock and bought 141,095 units worth $829,835 . The most active insiders traders include Gregory A Md Demopulos, Marcia S. Kelbon, and Daniel K Spiegelman. On average, Omeros executives and independent directors trade stock every 53 days with the average trade being worth of $97,792. The most recent stock trade was executed by Gregory A Md Demopulos on 17 November 2023, trading 15,000 units of OMER stock currently worth $25,200.



What does Omeros do?

omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.



What does Omeros's logo look like?

Omeros Corporation logo

Omeros executives and stock owners

Omeros executives and other stock owners filed with the SEC include: